Free Trial
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2023 Earnings Report

MAIA Biotechnology logo
$1.52 -0.05 (-3.18%)
Closing price 08/1/2025 04:10 PM Eastern
Extended Trading
$1.51 -0.01 (-0.66%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MAIA Biotechnology EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 6, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MAIA Biotechnology Earnings Headlines

This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA), a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat